Dosimetry
Measuring how much radiation dose each organ and tumour actually received from a radioactive drug.
Overview
Dosimetry is the measurement of how much radiation dose each organ and each tumour actually received from a radioactive drug. It relies on post-therapy SPECT/CT imaging at several time points and enables personalised activity prescription instead of fixed doses, and regulators and payers increasingly require it. The term is linked to the SPECT & bone scan and Radioligand therapy (beta emitters) technologies and to Radioembolisation (TARE / SIRT, yttrium-90), Auger-electron therapy and Total-body PET for screening. It is referenced by the Hepatocellular carcinoma and Neuroendocrine tumours entries, the radiopharmaceutical roadmap and the bottleneck on wrong doses, and by ideas on dosimetry-personalised PRRT instead of four fixed cycles and total-body PET for personalised radioligand dosing.
- Gamma camera (rotates)
- Single photons (Tc-99m, Lu-177)
Showing the technology this term belongs to: SPECT & bone scan.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
This document standardises how hospitals measure the actual radiation dose reaching a patient's kidneys and tumours during lutetium-177 treatment, laying the groundwork for shifting from a one-dose-fits-all schedule to treatment doses tailored to each patient's biology.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Similar pages
not linked directly; found by shared links- TermAlpha vs beta emitters
Shares Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit, Half-life, Alpha-emitter nanogenerators and daughter trapping, Wrong doses.
- TermTheranostics
Shares Inselspital, Bern University Hospital / University Cancer Center Inselspital, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours, PRRT (peptide receptor radionuclide therapy).
- BottleneckDosimetry standardisation for radioligand therapy
Shares Wrong doses, Dosimetry-personalised PRRT instead of four fixed cycles, Total-body PET for personalised radioligand dosing, European Association of Nuclear Medicine.
- AgentLutetium-177 dotatate
Shares Inselspital, Bern University Hospital / University Cancer Center Inselspital, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), Dosimetry-personalised PRRT instead of four fixed cycles, NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours.
- TermFixed versus personalised (dosimetry-guided) dosing
Shares Gray unit (Gy), Dosimetry-personalised PRRT instead of four fixed cycles, Total-body PET for personalised radioligand dosing, Yttrium-90.
- TargetSomatostatin receptor 2
Shares Auger-electron therapy, Inselspital, Bern University Hospital / University Cancer Center Inselspital, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours.
- AgentLutetium-177 vipivotide tetraxetan
Shares EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands, Alpha-emitting PSMA therapy at first metastatic diagnosis, Inselspital, Bern University Hospital / University Cancer Center Inselspital, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST).
- PersonKen Herrmann
Shares Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, European Association of Nuclear Medicine, Neuroendocrine tumours.